Prostate cancer prevention trials in the USA.
There is dramatic international variation in prostate cancer mortality rates. The variation suggests that the disease has an environmental cause and encourages the search for a way to prevent it. Androgenic stimulation over a period of time, perhaps due to a high fat diet, has been suggested as a cause of prostate cancer. The corollary to this hypothesis is that lowering androgenic stimulation over time will prevent prostate cancer. 5-Alpha-reductase inhibition through drugs like finasteride have been shown to decrease androgenic stimulation of the prostate. A clinical trial is underway using finasteride to assess this hypothesis. Epidemiological and laboratory studies also suggest that those with high selenium and vitamin E intake have a lower risk of prostate cancer. Recent serendipitous findings of two randomised clinical trials support this. A study to assess these compounds is currently being designed. Other promising but less developed interventions in the chemoprevention of prostate cancer include vitamin D supplementation and diet modification.
Brawley
O W
OW
National Cancer Institute, 6120 Executive Boulevard, EPS 320, Bethesda, MD 20852, USA. ob6g@nih.gov
Parnes
H
H
D058891:5-alpha Reductase Inhibitors; D000368:Aged; D000818:Animals; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D011817:Rabbits; D012307:Risk Factors; D012643:Selenium / Q000627:therapeutic use*; D014810:Vitamin E / Q000627:therapeutic use*
D058891:5-alpha Reductase Inhibitors; D004791:Enzyme Inhibitors; D014810:Vitamin E; D018120:Finasteride; D012643:Selenium